# Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma

> **NCT02364206** · PHASE1,PHASE2 · COMPLETED · sponsor: **Centre Jean Perrin** · enrollment: 18 (actual)

## Conditions studied

- Adult Glioblastoma

## Interventions

- **DRUG:** LY2228820
- **DRUG:** Temozolomide
- **RADIATION:** radiotherapy

## Key facts

- **NCT ID:** NCT02364206
- **Lead sponsor:** Centre Jean Perrin
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06-08
- **Primary completion:** 2019-08
- **Final completion:** 2019-08
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2019-08-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02364206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02364206, "Study of LY2228820 With Radiotherapy Plus Concomitant TMZ in the Treatment of Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02364206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*